menu
    • menu
    [{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pyridostigmine","moa":"Acetylcholinesterase","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aspen API","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Aspen API","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aspen API \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aspen API \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chugai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Mitem Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Deferoxamine Mesylate","moa":"Iron","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Mitem Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Mitem Pharma"},{"orgOrder":0,"company":"CNX Therapeutics","sponsor":"Erkim","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Dexrazoxane","moa":"Iron | DNA topoisomerase II","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"CNX Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CNX Therapeutics \/ Erkim","highestDevelopmentStatusID":"15","companyTruncated":"CNX Therapeutics \/ Erkim"},{"orgOrder":0,"company":"Rising Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Edetate Calcium Disodium","moa":"Metal ion","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Rising Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rising Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Rising Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Ohara Pharmaceutical","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"JAPAN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"Methotrexate","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Ohara Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ohara Pharmaceutical \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ohara Pharmaceutical \/ BTG Specialty Pharmaceuticals"},{"orgOrder":0,"company":"Serb","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"BELGIUM","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Glucarpidase","moa":"Methotrexate","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Serb","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Serb \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Serb \/ BTG Specialty Pharmaceuticals"},{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Acquisition","leadProduct":"Glucarpidase","moa":"Methotrexate","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BTG Specialty Pharmaceuticals \/ Serb","highestDevelopmentStatusID":"15","companyTruncated":"BTG Specialty Pharmaceuticals \/ Serb"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"SERB Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Agreement","leadProduct":"Glucarpidase","moa":"Methotrexate","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Atropine Sulfate","moa":"Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M2","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Injection","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"ASPR","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Atropine","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Meridian Medical Technologies","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Meridian Medical Technologies \/ ASPR","highestDevelopmentStatusID":"15","companyTruncated":"Meridian Medical Technologies \/ ASPR"},{"orgOrder":0,"company":"Kindeva Drug Delivery","sponsor":"US Department Of Health And Human Services","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"Atropine","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Kindeva Drug Delivery","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Kindeva Drug Delivery \/ US Department Of Health And Human Services","highestDevelopmentStatusID":"15","companyTruncated":"Kindeva Drug Delivery \/ US Department Of Health And Human Services"},{"orgOrder":0,"company":"Fennec Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Thiosulfate","moa":"Platinum\/protein complex","graph1":"Pharmacology\/Toxicology","graph2":"Approved FDF","graph3":"Fennec Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fennec Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Fennec Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aspen API

                            Netherlands
                            CPhI India
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothAspen API. More than just an API™

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : Glenmark Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Glenmark Acquires & Launches Acetylcysteine Injection 6gm/30mL Single-Dose Vials

                            Details : Glenmark has acquired generic version of Acetadote (acetylcysteine) injection from Aspen Pharma. It is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury.

                            Product Name : Acetadote-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 03, 2025

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : Glenmark Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            Aspen API Comapny Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CNX Therapeutics

                            United Kingdom arrow
                            Neuroscience
                            Not Confirmed

                            CNX Therapeutics

                            United Kingdom arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexrazoxane

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : Erkim

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Er-Kim Announces Agreement with CNX Therapeutics to Distribute Oncology Products

                            Details : The agreement creates an exclusive partnership for a portfolio of oncology-related medications, including CNX Therapeutics’ Cardioxane (dexrazoxane) and Savene (dexrazoxane).

                            Product Name : Cardioxane

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 26, 2025

                            Lead Product(s) : Dexrazoxane

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : Erkim

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Celltrion

                            South Korea arrow
                            Neuroscience
                            Not Confirmed

                            Celltrion

                            South Korea arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tocilizumab

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves Expanded Indication for Celltrion’s AVTOZMA

                            Details : Avtozma (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of cytokine release syndrome.

                            Product Name : Avtozma

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 11, 2025

                            Lead Product(s) : Tocilizumab

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kindeva Drug Delivery

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Kindeva Drug Delivery

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine,Pralidoxime Chloride

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : US Department Of Health And Human Services

                            Deal Size : $129.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Kindeva Secures $129M SNS Contract for Nerve Agent Antidote

                            Details : The funding aims to advance the the manufacturing of DuoDote (atropine and pralidoxime chloride). It is indicated for the treatment of poisoning by organophosphorus nerve agents.

                            Product Name : Duodote

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 16, 2025

                            Lead Product(s) : Atropine,Pralidoxime Chloride

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : US Department Of Health And Human Services

                            Deal Size : $129.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Fennec Pharmaceuticals

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Fennec Pharmaceuticals

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Thiosulfate

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fennec Pharmaceuticals Announces NICE Positive Recommendation for Pedmarqsi®

                            Details : Pedmarqsi (anhydrous sodium thiosulfate) is the first and only intracellular oxidative stress inhibitor, treatment available in England for cisplatin-induced ototoxicity in 1 month-17 years of age.

                            Product Name : Pedmarqsi

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            December 20, 2024

                            Lead Product(s) : Sodium Thiosulfate

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cumberland Pharmaceuticals

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Cumberland Pharmaceuticals

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves Acetadote® sNDA

                            Details : Acetadote (N-acetylcysteine) is a FDA approved drug candidate, which is now being evaluated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen.

                            Product Name : Acetadote

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 09, 2024

                            Lead Product(s) : Acetylcysteine

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pyridostigmine

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amneal Gains FDA Nod for Pyridostigmine Bromide Extended-Release Tablets

                            Details : Pyridostigmine Bromide, is a cholinesterase inhibitor small molecule drug administered orally for soman nerve agent poisoning in adults.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 21, 2024

                            Lead Product(s) : Pyridostigmine

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Neuroscience
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deferoxamine Mesylate

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : Mitem Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            MITEM Pharma Acquires DESFERAL® Rights Backed by TECHLIFE CAPITAL, MACSF

                            Details : Mitem acquires Desfera (deferoxamine mesylate) products from Novartis. It is indicated for treating iron overload, and forex, following blood transfusions necessary for treating beta-thalassemia.

                            Product Name : Desfera

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 25, 2024

                            Lead Product(s) : Deferoxamine Mesylate

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : Mitem Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Moksha8 Pharmaceuticals

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Moksha8 Pharmaceuticals

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : SERB Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            M8 Pharmaceuticals Signs Exclusive Agreement with SERB to Bring Voraxaze® to Latin America

                            Details : M8 will register, market and commercialize SERB's supportive oncology product Voraxaze (glucarpidase), a carboxypeptidase that reduces toxic plasma methotrexate concentration, in Latin America.

                            Product Name : Voraxaze

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            March 20, 2024

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : SERB Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Meridian Medical Technologies

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed

                            Meridian Medical Technologies

                            U.S.A arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine,Pralidoxime Chloride

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved FDF

                            Sponsor : ASPR

                            Deal Size : $9.9 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Meridian Medical Technologies, Kindeva Drug Delivery’s Global Health Security Division, Awarded Contract to ...

                            Details : Under the agreement, Meridian will supply DuoDote to the Administration for Strategic Preparedness and Response within the United States. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent anti...

                            Product Name : DuoDote

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 14, 2023

                            Lead Product(s) : Atropine,Pralidoxime Chloride

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved FDF

                            Sponsor : ASPR

                            Deal Size : $9.9 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth